Is para‑aortic lymph node metastasis considered regional disease in ovarian cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, para-aortic lymph node metastasis is considered regional disease in ovarian cancer, classified as Stage IIIC disease.

According to the FIGO staging system for ovarian cancer, para-aortic lymph node metastases represent Stage IIIC disease, which is regional rather than distant metastatic disease. This is a critical distinction that affects both prognosis and treatment planning 1, 2, 3, 1.

FIGO Staging Classification

The staging system clearly delineates lymph node involvement:

  • Stage IIIC: Peritoneal metastasis beyond the pelvis >2 cm in diameter and/or regional lymph node metastasis 1
  • Stage IV: Distant metastases including parenchymal liver metastases or extra-abdominal sites 1

The 2014 revised FIGO staging further refined this by subdividing Stage IIIA1 to specifically address retroperitoneal lymph nodes (both pelvic and para-aortic), with Stage IIIA1(i) for nodal metastases ≤10 mm and Stage IIIA1(ii) for nodal metastases >10 mm 2. This classification explicitly defines para-aortic nodes as regional, not distant disease.

Clinical Implications

Para-aortic lymph node involvement carries important prognostic significance but remains within the regional disease category:

  • Patients with only nodal metastases (without peritoneal disease above the pelvic brim) have relatively favorable outcomes compared to other Stage III presentations 2
  • The distinction from Stage IV (distant metastases) is crucial because regional nodal disease is treated with curative intent using cytoreductive surgery and platinum-based chemotherapy 3

Surgical Staging Requirements

Complete surgical staging for ovarian cancer mandates assessment of both pelvic and para-aortic lymph nodes 1, 4, 3, 1. The guidelines emphasize:

  • Systematic pelvic and para-aortic lymphadenectomy is recommended for staging purposes, particularly in high-grade histologies 5
  • Para-aortic lymph node dissection should extend up to the level of the left renal vein 6
  • In apparent early-stage disease, 15% of patients have microscopically positive lymph nodes, with 36% having positive para-aortic nodes among those with nodal involvement 3

Distribution Patterns

Research demonstrates that para-aortic involvement can occur in several patterns 7, 6, 8:

  • Both pelvic and para-aortic nodes: 35.9-55% of cases with nodal metastases
  • Para-aortic nodes only (without pelvic involvement): 13.3-20%
  • Pelvic nodes only: 13.3-15%

This isolated para-aortic involvement pattern (without pelvic nodes) in 13-20% of cases reinforces that para-aortic nodes are part of the regional lymphatic drainage system for ovarian cancer, not distant metastases.

Key Caveat

Extra-abdominal lymph nodes (such as inguinal or supraclavicular nodes) are classified as Stage IVB distant metastases, not regional disease 2. The regional designation applies specifically to retroperitoneal (pelvic and para-aortic) lymph nodes within the abdomen.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.